全文获取类型
收费全文 | 1580篇 |
免费 | 113篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 79篇 |
妇产科学 | 32篇 |
基础医学 | 183篇 |
口腔科学 | 40篇 |
临床医学 | 121篇 |
内科学 | 422篇 |
皮肤病学 | 32篇 |
神经病学 | 106篇 |
特种医学 | 34篇 |
外科学 | 215篇 |
综合类 | 12篇 |
预防医学 | 142篇 |
眼科学 | 70篇 |
药学 | 103篇 |
中国医学 | 6篇 |
肿瘤学 | 95篇 |
出版年
2023年 | 22篇 |
2022年 | 28篇 |
2021年 | 49篇 |
2020年 | 34篇 |
2019年 | 63篇 |
2018年 | 51篇 |
2017年 | 37篇 |
2016年 | 36篇 |
2015年 | 54篇 |
2014年 | 66篇 |
2013年 | 85篇 |
2012年 | 88篇 |
2011年 | 102篇 |
2010年 | 64篇 |
2009年 | 45篇 |
2008年 | 84篇 |
2007年 | 86篇 |
2006年 | 88篇 |
2005年 | 66篇 |
2004年 | 61篇 |
2003年 | 88篇 |
2002年 | 73篇 |
2001年 | 42篇 |
2000年 | 37篇 |
1999年 | 22篇 |
1998年 | 7篇 |
1997年 | 12篇 |
1996年 | 7篇 |
1995年 | 7篇 |
1994年 | 6篇 |
1992年 | 13篇 |
1991年 | 11篇 |
1990年 | 16篇 |
1989年 | 19篇 |
1988年 | 15篇 |
1987年 | 14篇 |
1986年 | 11篇 |
1985年 | 11篇 |
1984年 | 8篇 |
1983年 | 10篇 |
1980年 | 4篇 |
1979年 | 4篇 |
1978年 | 6篇 |
1977年 | 4篇 |
1975年 | 6篇 |
1973年 | 3篇 |
1971年 | 4篇 |
1970年 | 4篇 |
1969年 | 3篇 |
1965年 | 3篇 |
排序方式: 共有1698条查询结果,搜索用时 15 毫秒
41.
42.
43.
Josh W. Pressler April Haller Joyce Sorrell Fei Wang Randy J. Seeley Patrick Tso Darleen A. Sandoval 《Diabetes》2015,64(2):498-507
Bariatric surgery is the most successful strategy for treating obesity, yet the mechanisms for this success are not clearly understood. Clinical literature suggests that plasma levels of apolipoprotein A-IV (apoA-IV) rise with Roux-en-Y gastric bypass (RYGB). apoA-IV is secreted from the intestine postprandially and has demonstrated benefits for both glucose and lipid homeostasis. Because of the parallels in the metabolic improvements seen with surgery and the rise in apoA-IV levels, we hypothesized that apoA-IV was necessary for obtaining the metabolic benefits of bariatric surgery. To test this hypothesis, we performed vertical sleeve gastrectomy (VSG), a surgery with clinical efficacy very similar to that for RYGB, in whole-body apoA-IV knockout (KO) mice. We found that VSG reduced body mass and improved both glucose and lipid homeostasis similarly in wild-type mice compared with apoA-IV KO mice. In fact, VSG normalized the impairment in glucose tolerance and caused a significantly greater improvement in hepatic triglyceride storage in the apoA-IV KO mice. Last, independent of surgery, apoA-IV KO mice had a significantly reduced preference for a high-fat diet. Altogether, these data suggest that apoA-IV is not necessary for the metabolic improvements shown with VSG, but also suggest an interesting role for apoA-IV in regulating macronutrient preference and hepatic triglyceride levels. Future studies are necessary to determine whether this is the case for RYGB as well. 相似文献
44.
Coral Parikh Victoria Gutgarts Elliot Eisenberg Michal L. Melamed 《Seminars in dialysis》2015,28(6):604-609
Most dialysis patients are vitamin D deficient, including deficiencies in both activated vitamin D (1, 25‐dihydroxyvitamin D) and the less active 25‐hydroxyvitamin D. These and other abnormalities associated with chronic kidney disease (CKD), if they remain untreated, lead to secondary hyperparathyroidism and bone changes, such as osteitis fibrosa cystica. Activated vitamin D has been proven to decrease parathyroid hormone (PTH) levels in dialysis patients and is currently used for this indication. There are multiple other potential “pleotrophic” effects associated with vitamin D therapy. These include associations with lower all‐cause and cardiovascular mortality, lower rates of infections and improved glycemic indexes. Meta‐analyses of multiple observational studies have shown activated vitamin D therapy to be associated with improved survival. Observational data also suggest fewer infections and better glucose control. There have been no randomized clinical trials powered to evaluate mortality or other clinical outcomes. Small trials of nutritional vitamin D (ergocalciferol and cholecalciferol) showed increases in 25‐hydroxyvitamin D levels without hypercalcemia or hyperphosphatemia, even when given in addition to activated vitamin D therapy. While activated vitamin D therapy is associated with improved outcomes, it also leads to higher fibroblast growth factor 23 (FGF‐23) levels, which may be detrimental in dialysis patients. Further research is needed to evaluate whether activated or nutritional vitamin D therapy are beneficial in dialysis patients for outcomes other than secondary hyperparathyroidism. 相似文献
45.
46.
47.
48.
49.